BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. 

It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA and Health Canada. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. 

As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award.

Learn more at https://biocina.com.


Biotechnology

Life Sciences

Pharmaceutical

BioCina

BioCina's headquarters in Thebarton, Australia

Mark W. Womack

Peter Bullard

Scott Dassira

Jason Arcediano

Michael Tsaconas

Melissa El Khouri

BioCina

Org chart

Teams

Offices

Similar companies